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Abstract
Background: Glutamate (Glu) is essential to central nervous system function; however excessive Glu release leads to
neurodegenerative disease. Strategies to protect neurons are underdeveloped, in part due to a limited understanding of
natural neuroprotective mechanisms, such as those present in the suprachiasmatic nucleus (SCN). This study tests the
hypothesis that activation of ERK/MAPK provides essential protection to the SCN after exposure to excessive Glu using the
SCN2.2 cells as a model.
Methodology: Immortalized SCN2.2 cells (derived from SCN) and GT1-7 cells (neurons from the neighboring hypothalamus)
were treated with 10 mM Glu in the presence or absence of the ERK/MAPK inhibitor PD98059. Cell death was assessed by
Live/Dead assay, MTS assay and TUNEL. Caspase 3 activity was also measured. Activation of MAPK family members was
determined by immunoblot. Bcl2, neuritin and Bid mRNA (by quantitative-PCR) and protein levels (by immunoblot) were
also measured.
Principal Findings: As expected Glu treatment increased caspase 3 activity and cell death in the GT1-7 cells, but Glu alone
did not induce cell death or affect caspase 3 activity in the SCN2.2 cells. However, pretreatment with PD98059 increased
caspase 3 activity and resulted in cell death after Glu treatment in SCN2.2 cells. This effect was dependent on NMDA
receptor activation. Glu treatment in the SCN2.2 cells resulted in sustained activation of the anti-apoptotic pERK/MAPK,
without affecting the pro-apoptotic p-p38/MAPK. In contrast, Glu exposure in GT1-7 cells caused an increase in p-p38/MAPK
and a decrease in pERK/MAPK. Bcl2-protein increased in SCN2.2 cells following Glu treatment, but not in GT1-7 cells; bid
mRNA and cleaved-Bid protein increased in GT1-7, but not SCN2.2 cells.
Conclusions: Facilitation of ERK activation and inhibition of caspase activation promotes resistance to Glu excitotoxicity in
SCN2.2 cells.
Significance: Further research will explore ERK/MAPK as a key molecule in the prevention of neurodegenerative processes.
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Introduction
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s,
Huntington’s and Stroke have no cure, and represent a major
source of morbidity and mortality in western society. Once the
process of neurodegeneration begins, therapies and treatments to
reverse or prevent neuronal loss are scarce. A major factor
contributing to the paucity of treatment options is the lack of
fundamental understanding of cellular processes leading to cell
demise. An additional obstacle is insufficient comprehension of
mechanisms utilized by cells to protect themselves from death in
the face of the neurotoxic insults [1] that accompany degenerative
processes. Excessive glutamate (Glu) release is a primary cause of
neuronal death in several neurodegenerative disorders [2,3,4].
Thus, the responsiveness of a cell population (such as the SCN2.2
cells) to large amounts of Glu may be key to understanding
neuroprotection and neurodegeneration.
The SCN has been widely studied for its role as a circadian
pacemaker [5,6,7,8,9,10,11,12,13,14]. Although the SCN is
renowned for its resistance to glutamate excitotoxicity [15,16,
17,18,19,20], mechanisms underlying this endogenous neuropro-
tection remain obscure. Recently, we demonstrated, for the first
time, that the SCN2.2 cell line, which is derived from rat SCN,
retains resistance to Glu excitotoxicity, [1]. This study represents
an initial foray into determining the mechanisms and signaling
pathways involved in SCN2.2 cell resistance to Glu excitotoxicity.
Mitogen-activated protein kinases (MAPKs) are signal trans-
ducers that have been implicated in cellular events resulting in
both cell death [21] and survival [22]. Of the three major
mammalian MAPK proteins, the extracellular regulated kinase/
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survival [23], whereas p38/MAPK [24] and stress activated
protein kinase/Jun N-terminal kinase (SAPK/JNK) pathways are
often implicated in cell death [25,26]. The signal transduction
pathways for each of these kinases have been extensively
elucidated in cancer studies. Interestingly, however, MAPKs are
also essential for regulating physiological responses to light and
Glu in the SCN in vivo [27]. Therefore, we have explored the roles
of MAPKs in SCN2.2 cells in an effort to address whether the
mechanistic pathway for endogenous neuroprotection in the
SCN2.2 cells depends on the MAPK signaling cascade.
Results
ERK/MAPK Inhibitor PD98059 Induces NMDAR-Mediated
Cell Death in SCN2.2 Cells
For all experiments GT1-7 neurons were used as a positive
control as they are susceptible to Glu-induced cell death. GT1-7
and SCN2.2 cells were exposed to the following treatments: 1)
normal culture conditions (control); 2) 10 mM of the ERK/MAPK
inhibitor PD98059 (PD); 3) 10 mM Glu (Glu) or 4) 10 mM
Glu+10 mM PD98059 (Glu+PD). Cell viability was analyzed with
the Live/Dead assay. All treatments were for 48 h, except that
PD98059 was added 1 h prior to the 48 h Glu incubation in the
Glu+PD group. Two-way ANOVA analysis was conducted to
assess the effects of cell type and treatment, as well as the
interaction of these two factors. Results of overall two-way
ANOVA analysis are presented in Table 1. Both cell type (GT1-
7 or SCN2.2) and treatment (control, PD, Glu or Glu+PD) as well
as the interaction of cell type and treatment had significant effects
on the number of live cells. Bonferroni’s post hoc test showed that
GT1-7 live cells were significantly decreased from control in both
the Glu and Glu+PD treatment groups (Figure 1A, d=p,0.0001),
whereas SCN2.2 live cells were significantly decreased only in the
Glu+PD treatment group when compared to control (Figure 1A,
d=p,0.0001). Fold change from control for GT1-7 vs. SCN2.2
live cells were significantly different from each other only for the
Glu treatment group (Figure 1A, ****=p,0.0001); with all other
treatment conditions there was no significant difference between
the cell lines.
Similar two-way ANOVA analysis of dead cell results
demonstrated a significant effect of treatment (control, PD, Glu
or GLU+PD) but not cell type (GT1-7 or SCN2.2); the interaction
of cell type and treatment also significantly affected the number of
dead cells (Table 1). Bonferroni’s post hoc test determined that
among the GT1-7 neurons, both the Glu treatment (Figure 1B,
b=p,0.01) and the Glu+PD treatment (Figure 1B, d=p,0.0001)
resulted in an increased number of dead cells compared to control.
Within the SCN2.2 cells however, only the control vs. Glu+PD
treatment produced increased dead cells (Figure 1B,
d=p,0.0001). Bonferroni’s post hoc comparison for fold change
showed fewer dead cells in the SCN2.2 vs. GT1-7 cells in the Glu
treatment group (Figure 1B, **=p,0.01); but following the
Glu+PD treatment, SCN2.2 cells displayed higher numbers of
dead cells than the GT1-7 cells (Figure 1B, *=p,0.05).
The results from the Live/Dead assay are consistent with
previous findings from our lab [1], demonstrating that 48 h of
10 mM Glu treatment alone induced cell death in GT1-7 but not
in the SCN2.2 cells (Figure 1A and 1B). However, 1 h pre-
treatment with 10 mM of the ERK/MAPK inhibitor PD98059
and 48 h concurrent treatment with PD98059 and Glu resulted in
a significant decrease in live SCN2.2 cells (Figure 1A) as well as a
concomitant increase in dead cells (Figure 1B). Thus, inhibiting
ERK/MAPK activity compromised the endogenous neuroprotec-
tive mechanism in SCN2.2 against Glu toxicity.
To determine whether NMDAR-mediated signaling was
involved in the increased susceptibility to excitotoxicity in
SCN2.2 cells exposed to the ERK/MAPK inhibitor PD98059,
cells were pre-treated for 1 h with an NMDAR blocker, MK-801,
before receiving the excitotoxin NMDA plus PD98059 and MK-
801 for 48 h, with appropriate controls. GT1-7 cells were used as a
positive control. The experiment included eight treatment groups
for each cell type, as follows: 1) Untreated control (control); 2)
10 mM PD98059 (PD); 3) 10 mM MK-801 (MK); 4) 10 mM
PD98059+10 mM MK-801 (PD+MK); 5) 50 mM NMDA+10 mM
MK-801 (NMDA+MK); 6) 50 mM NMDA+10 mM MK-
801+10 mM PD98059 (NMDA+MK+PD); 7) 50 mM NMDA
(NMDA) and 8) 50 mM NMDA+10 mM PD98059 (NMDA+PD).
Cell viability was determined using the MTS assay to measure
cellular metabolic activity. The results were analyzed with two-
way ANOVA, using Bonferroni’s post hoc test. There was a
significant effect of treatment (control, PD, MK, PD+MK,
NMDA+MK, NMDA+MK+PD, NMDA or NMDA+PD), but
not cell type (GT1-7 or SCN2.2) on metabolic activity in these
Table 1. Results of Two-way ANOVA Analysis.
Figure Cell Type (GT1-7 vs. SCN2.2)
Treatment (condition or time vs.
control)
Interaction of Cell Type and
Treatment
1A; Live Cells p,0.0001 p,0.0001 p,0.0001
1B; Dead Cells ns (p=0.48) p,0.0001 p,0.01
1C; MTS assay ns (p=0.82) p,0.0001 p,0.01
1D; MTS assay ns (p=.28) p,0.0001 p,0.01
3A; pERK/MAPK p,0.0001 p,0.0001 p,0.0001
3B; p-p38/MAPK p,0.0001 ns (p=0.17) ns (p=0.09)
3C; p-SAPK/JNK p,0.0001 p,0.05 p,0.01
5A; Neuritin p,0.0001 p,0.05 ns (p=0.10)
5B; Bcl2 ns (p=0.32) p,0.0001 p,0.0001
5C; Bid p,0.0001 p,0.0001 p,0.0001
Two-way ANOVA analysis with Bonferroni’s post hoc correction was used to analyze data in figures 1, 3 and 5. Results of the overall analysis are presented; post hoc
analysis p values are given in the text and figures. Statistics were done with GraphPad Prism 5.0.
doi:10.1371/journal.pone.0023493.t001
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metabolic activity was also significant (Table 1). Within the GT1-7
cells, both the NMDA and the NMDA+PD treatment groups had
significantly reduced metabolic activity compared to controls
(Figure 1C, c=p,0.001); whereas among the SCN2.2 cells only
the NMDA+PD treatment group showed reduced metabolic
activity compared to control (Figure 1C, c=p,0.001). Additional
Bonferroni’s post hoc analysis compared fold change for GT1-7 vs.
SCN2.2 cells in each treatment group. The GT1-7 cells had
reduced metabolic activity compared to SCN2.2 cells only for the
NMDA treatment group (Figure 1C, **=p,0.01). As expected,
NMDA treatment for 48 h reduced metabolic activity in the GT1-
7 cells as compared with control, but this reduction was prevented
by MK-801. Also as expected, SCN2.2 cell metabolic activity
remained unaffected by NMDA treatment. However, PD98059
severely reduced metabolic activity of NMDA-treated SCN2.2
cells. The effect of NMDA and PD98059 on SCN2.2 cells was
prevented by MK-801. Thus, NMDARs may lie upstream of
ERK/MAPK activation in SCN2.2 cell resistance to excitotoxic-
ity.
We performed similar experiments in which NMDA was
replaced by glutamate (Figure 1D). The results were analyzed
with two-way ANOVA, using Bonferroni’s post hoc test. There
was a significant effect of treatment (control, PD, MK, PD+MK,
Glu+MK, Glu+MK+PD, Glu or Glu+PD), but not cell type (GT1-
7 or SCN2.2) on metabolic activity in these cells (Table 1). The
interaction between treatment and cell type on metabolic activity
was significant (Table 1). Within the GT1-7 cells, both the Glu and
the Glu+PD treatment groups had significantly reduced metabolic
activity compared to controls (Figure 1D, c=p,0.001); whereas
in the SCN2.2 cells the Glu group was unchanged from control,
but both the Glu+MK+PD and the Glu+PD treatment groups
showed reduced metabolic activity compared to control
(Figure 1D, b=p,0.01 and d=p,0.0001). Thus in the SCN2.2
Figure 1. ERK/MAPK Inhibitor PD98059 Induces NMDAR-Mediated Cell Death in SCN2.2 Cells. A: Live cells in GT1-7 and SCN2.2 cultures
exposed to normal culture conditions (control); 10 mM PD98059 (PD); 10 mM Glu (Glu); or 10 mM Glu+10 mM PD98059 (Glu+PD) for 48 h. PD98059
was added 1 h prior to Glu, and continued throughout Glu treatment. Live cells were measured with the Live/Dead assay. Results are mean 6 SD
from 2 experiments with n=18 in each. B: Dead cells as measured by Live/Dead assay for same samples as in A. C: % Metabolic activity in GT1-7 and
SCN2.2 cultures exposed to normal culture conditions (control); 10 mM PD98059 (PD); 10 mM MK-801 (MK); 10 mM PD98059+10 mM MK-801 (PD+MK);
50 mM NMDA+10 mM MK-801 (NMDA+MK); 50 mM NMDA+10 mM MK-801+10 mM PD98059 (NMDA+MK+PD); 50 mM NMDA (NMDA); or 50 mM
NMDA+10 mM PD98059 (NMDA+PD) for 48 h. Inhibitors were added 1 h prior to NMDA. Metabolic activity was measured with the MTS assay. Results
are mean 6 SD from 2 experiments with n=12 each. D: % Metabolic activity in GT1-7 and SCN2.2 cultures exposed to normal culture conditions
(control); 10 mM PD98059 (PD); 10 mM MK-801 (MK); 10 mM PD98059+10 mM MK-801 (PD+MK); 10 mM Glu+10 mM MK-801 (NMDA+MK); 10 mM
Glu+10 mM MK-801+10 mM PD98059 (Glu+MK+PD); 10 mM Glu (Glu); or 10 mM Glu+10 mM PD98059 (NMDA+PD) for 48 h. Inhibitors were added 1 h
prior to Glu. Metabolic activity was measured with the MTS assay. Results are mean 6 SD from 2 experiments with n=12 each. All data analyzed by
two-way ANOVA with Bonferroni’s post hoc test. Comparisons of GT1-7 vs. SCN2.2 within a treatment group are indicated by: *=p,0.05;
**=p,0.01; ***=p,0.001; ****=p,0.0001. Comparisons of treatment groups vs. control within either GT1-7 or SCN2.2 cells are indicated by:
b=p,0.01; c=p,0.001; d=p,0.0001.
doi:10.1371/journal.pone.0023493.g001
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suggests that SCN2.2 cell death in the Glu+PD treatment group
could be mediated in part by a non-NMDA pathway.
ERK/MAPK inhibition induces cell death in SCN2.2 cells
via an apoptotic pathway
To explore whether cell death caused by excitotoxicity in the
presence of the ERK/MAPK blocker PD98059 occurs via apoptosis,
the following treatments were applied to cultured cells: 1) untreated
control (control); 2) 10 mM PD98059 (PD); 3) 10 mM Glu and 4)
10 mM Glu+10 mM PD98059 (Glu+PD). PD98059 was added 1 h
prior to Glu and continued throughout the 48 h treatment period.
Apoptosis was assessed in 3 ways: 1) cleaved caspase 3 immunocy-
tochemistry; 2) TUNEL and 3) caspase 3 activity assay. All 3
experimental methods produced consistent results.
Treatment of SCN2.2 cellswithPD98059+G l uresu l te dinin cre a sed
cleaved caspase 3 immunostaining (Figure 2A) and increased TUNEL-
positive cells (Figure 2B). Similarly, caspase 3 activity increased
significantly in SCN2.2 cells when Glu was added in the presence of
PD98059 (Figure 2C, ***=p,0.001) as measured by repeated
measures ANOVA with Tukey’s post hoc comparison. Control
medium replacement, PD98059 alone and Glu alone produced no
significant change in any of these parameters in SCN2.2 cells.
Preferential activation of ERK/MAPK in response to Glu in
SCN2.2 cells
Immunoblot analysis allowed comparisons of pERK/MAPK, p-
p38/MAPK and pSAPK-JNK/MAPK in response to Glu in
SCN2.2 and GT1-7 cells. SCN2.2 and GT1-7 cells were treated
with 10 mM Glu for different lengths of time (control=0 min,
5 min, 10 min, 30 min, 1 h, 4 h and 12 h), and cells were collected
for immunoblot analysis of pERK/MAPK, p-p38/MAPK and p-
SAPK/JNK/MAPK. Results were analyzed by two-way ANOVA
with Bonferroni’s post hoc test with treatment and cell type as the
dependent variables. pERK/MAPK was significantly affected by
both cell type (GT1-7 or SCN2.2) and treatment time (control,
Figure 2. ERK/MAPK Inhibition Induces Cell Death in SCN2.2 Cells via an Apoptotic Pathway. A: Immunocytochemistry for activated
caspase 3 in SCN2.2 cells exposed to: untreated control (control); 10 mM PD98059 (PD); 10 mM Glu (Glu) or 10 mM Glu+10 mM PD98059 (Glu+PD) for
48 h. Results from typical experiments are shown; 3 different experiments with n=2 for each experiment were performed. B: TUNEL assay in SCN2.2
cells treated with the same conditions as in A. Results from typical experiments are shown; 3 different experiments with n=2 for each experiment
were performed. C: Caspase 3 activity in SCN2.2 cells treated with the same conditions as in A. Results are mean 6 SEM for 3 experiments with n=2
each. Comparisons of treatment groups vs. control in C were analyzed with repeated measures ANOVA and Tukey’s post hoc comparison.
***=p,0.001.
doi:10.1371/journal.pone.0023493.g002
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these two factors was also significant (Table 1). ERK/MAPK
phosphorylation did not significantly change in GT1-7 cells
compared to control for up to 12 h (Figure 3A). After 48 h, a
significant decrease in pERK/MAPK was observed in GT1-7 cells
compared to control by t-test (Figure 4A, *=p,0.05). In contrast,
Glu treatment strongly and consistently induced phosphorylation of
ERK/MAPK in SCN2.2 at 5 min (Figure 3A, c=p,0.001),
10 min (Figure 3A, a=p,0.0.05), 30 min (Figure 3A, b=p,0.01),
4 h (Figure 3A, a=p,0.05), and 12 h (Figure 3A, d=p,0.0001)
compared to control. Increased SCN2.2 pERK/MAPK was
maintained at 48 h when control and 48 h samples were compared
by t-test (Figure 4A, *=p,0.05). A significantly higher induction of
pERK/MAPK was observed in SCN2.2 vs. GT1-7 cells at multiple
time points including: 5 min (Figure 3A, ****=p,0.0001); 10 min
(Figure 3A, **=p,0.01); 30 min (Figure 3A, ***=p,0.0001); 1 h
(Figure 3A, *=p,0.05) and 12 h (Figure 3A, ****=p,0.0001).
Simultaneously, we also probed for p-p38/MAPK and analyzed
results by two-way ANOVA with treatment and cell type as the
dependent variables. p-p38/MAPK was significantly affected by
cell type (GT1-7 or SCN2.2) but not treatment time (control,
5 min, 10 min, 30 min, 1 h, 4 h or 12 h); the interaction between
these two factors was not significant (Table 1). Because the
interaction of the two factors was not significant, it can only be said
that the average of all GT1-7 p-p38/MAPK was greater than the
average of all SCN2.2 p-p38/MAPK (p,0.001). There was no
significant difference between any time points for either cell type.
Comparison of the GT1-7 48 h Glu treatment to control by t-test
indicated that p-p38/MAPK was significantly higher after
treatment (Figure 4B, p,0.05). In contrast, Glu had no significant
effect on p-p38/MAPK compared to control in SCN2.2 cells
(Figure 3B and Figure 4B).
We also probed for pSAPK/JNK and analyzed results by two-
way ANOVA with Bonferroni’s post hoc test using treatment and
Figure 3. Preferential Activation of ERK/MAPK in Response to Glu in SCN2.2 Cells. A: Immunoblot for pERK/MAPK in GT1-7 and SCN2.2
cells exposed to 10 mM Glu for 0 min (control), 5 min, 10 min, 30 min, 1 h, 4 h and 12 h. Sample blots are shown on the left, quantification of blots
are displayed on the right. B: Immunoblot for p-p38/MAPK in GT1-7 and SCN2.2 cells exposed to 10 mM Glu for the same time periods as in A.
Sample blots are shown on the left, quantification of blots are displayed on the right. C: Immunoblot for pSAPK-JNK/MAPK in GT1-7 and SCN2.2 cells
exposed to 10 mM Glu for the same time periods as in A. Sample blots are shown on the left, quantification of blots are displayed on the right. All
experiments were repeated 3 or 4 times, with n=1 per experiment. Data were analyzed by two-way ANOVA with post hoc Bonferroni’s test. For
pERK/MAPK and pSAPK-JNK/MAPK where two-way ANOVA showed a significant interaction between cell type and treatment time, comparisons of
GT1-7 vs. SCN2.2 within a time point are indicated by: *=p,0.05; **=p,0.01; ***=p,0.001, ****=p,0.0001. For pERK/MAPK and pSAPK-JNK/MAPK
comparisons of time points vs. control (0 min) within either GT1-7 or SCN2.2 cells are indicated by: a=p,0.05; b=p,0.01; c=p,0.001;
d=p,0.0001. For p-p38/MAPK, where two-way ANOVA did not show a significant interaction between cell type and treatment time, comparison
between cell types as a whole (not broken down by treatment time) is indicated by ****=p,0.001.
doi:10.1371/journal.pone.0023493.g003
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affected by cell type (GT1-7 or SCN2.2) and treatment time
(control, 5 min, 10 min, 30 min, 1 h, 4 h or 12 h); the interaction
between these two factors was also significant (Table 1). Glu
treatment did not significantly alter pSAPK/JNK/MAPK in GT1-
7 cells (Figure 3C and Figure 4C). In contrast, Glu treatment caused
a transient increase in pSAPK/JNK/MAPK in SCN2.2 cells only
at 10 min (Figure 3 C, a=p,0.05) and 30 min (Figure 3C,
c=p,0.01) compared to control (Figure 3C and Figure 4C).
Cell signaling downstream of ERK/MAPK pathway
activation in cell survival promotion
To determine what signaling molecules activated downstream of
ERK/MAPK might be associated with protection in SCN2.2 cells,
changes in transcript levels for several prosurvival and proapopto-
tic factors were examined by qPCR and changes in protein levels
were assessed with immunoblot following incubation with 10 mM
Glu vs. media change (control). Neuritin plays a role in neurite
outgrowth and synapse formation. Neuritin mRNA results were
analyzed by two-way ANOVA using treatment and cell type as the
dependent variables. Neuritin mRNA was significantly affected
both by cell type (GT1-7 or SCN2.2) and treatment time (control,
6, 12, 18, 24, 36 or 48 h); however the interaction between these
two factors was not significant (Table 1). Thus it can only be said
that neuritin mRNA in SCN2.2 (irrespective of treatment time)
was significantly higher than Neuritin mRNA in all GT1-7
(p,0.0001) (Figure 5A). Neuritin mRNA (ignoring cell type) was
significantly increased at 36 h compared to control (Figure 5A,
a=p,0.05). Neuritin protein was measured after 48 h incubation
with Glu and compared with control by t-test. Neither GT1-7 nor
SCN2.2 cells showed a significant change in neuritin protein
following 48 hr incubation with 10 mM Glu.
Figure 4. Activation of pERK/MAPK is Sustained for 48 h in SCN2.2 Cells Exposed to Glu. A: Immunoblot for pERK/MAPK in GT1-7 and
SCN2.2 cells treated with media change (control) or 10 mM Glu for 48 h. Sample blots are shown on the left, quantification of blots are displayed on
the right. B: Immunoblot for p-p38/MAPK in GT1-7 and SCN2.2 cells treated with media change (control) or 10 mM Glu for 48 h. Sample blots are
shown on the left, quantification of blots are displayed on the right. C: Immunoblot for pSAPK-JNK/MAPK in GT1-7 and SCN2.2 cells treated with
media change (control) or 10 mM Glu for 48 h. Sample blots are shown on the left, quantification of blots are displayed on the right. All experiments
were repeated 3 or 4 times, with n=1 per experiment. Data were analyzed by paired samples t test for control vs. 48 h; *=p,0.05.
doi:10.1371/journal.pone.0023493.g004
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survival; it blocks the activation of caspases and prevents apoptosis.
Bcl2 mRNA was analyzed by two-way ANOVA with Bonferroni’s
post hoc test using treatment and cell type as the dependent
variables. Treatment time (control vs. 6, 12, 18, 24, 36 and 48 h),
but not cell type (GT1-7 vs. SCN2.2), significantly influenced Bcl2
mRNA levels; the interaction between treatment time and cell type
was also significant (Table 1). Bcl2 mRNA initially increased in
GT1-7 time points compared with control at 6 h (Figure 5B,
d=p,0.0001), 12 h (Figure 5B, c=p,0.01) and 18 h (Figure 5B,
a=p,0.05). At all other time points Bcl2 mRNA was not
increased vs. control (Figure 5B). There was no significant change
in SCN2.2 Bcl2 mRNA at any time point (Figure 5B). After both
6 h (Figure 5B, ****=p,0.0001) and 12 h (Figure 5,
***=p,0.001) incubation with Glu, GT1-7 Bcl2 mRNA was
significantly increased vs. SCN2.2 Bcl2. At all other time points
there was no difference between GT1-7 and SCN2.2 Bcl2 mRNA
(Figure 5B). Bcl2 protein was measured after 48 h incubation with
Glu and compared with control by t-test and levels did not change
in GT1-7 cells (Figure 5B). Surprisingly, although SCN2.2 mRNA
for Bcl2 did not change over a 48 h period, Bcl2 protein levels did
significantly increase in the 48 h treatment vs. control (Figure 5B,
**=p,0.01).
Bid is a pro-apoptotic molecule; cleavage of Bid heralds
apoptotic processes that are dependent on the mitochondrial
pathway. Bid mRNA was analyzed by two-way ANOVA with
Bonferroni’s post hoc test using treatment and cell type as
dependent variables. Both treatment time (control vs. 6, 12, 18, 24,
36 and 48 h) and cell type (GT1-7 vs. SCN2.2) significantly
influenced Bid mRNA levels; the interaction between treatment
time and cell type was also significant (Table 1). Bid mRNA
showed a sustained increased in GT1-7 cells at 6 h (Figure 5C,
Figure 5. Cell Signaling Downstream of ERK/MAPK Pathway. A: mRNA for neuritin in GT1-7 and SCN2.2 cells treated with media change
(control) or 10 mM Glu for 6, 12, 18, 24, 36 and 48 h. Immunoblots for neuritin protein in GT1-7 and SCN2.2 cells treated with Glu or control for 48 h
are also shown, along with their quantification. B: mRNA for Bcl2 in GT1-7 and SCN2.2 cells treated in the same way as in A. Immunoblots for Bcl2
protein in GT1-7 and SCN2.2 cells treated with Glu or control for 48 h are also shown, along with their quantification. C: mRNA for Bid in GT1-7 and
SCN2.2 cells treated in the same was as in A. Immunoblots for cleaved Bid protein in GT1-7 cells treated with Glu or control for 48 h are also shown,
along with their quantification. No suitable antibody was found for cleaved Bid in SCN2.2. PCR data is the average of 2 experiments with n=3 for
each experiment. The Immunoblots are the average of 3 to 4 experiments with n=1 each. mRNA data were analyzed by two-way ANOVA with
Bonferroni’s post hoc comparison; immunoblot data were compared using paired t test. For Bcl2 and Bid, where two-way ANOVA was significant for
an interaction between cell type and treatment time, comparisons of GT1-7 mRNA vs. SCN2.2 mRNA within a time point are indicated by: *=p,0.05;
**=p,0.01; ***=p,0.001, ****=p,0.0001. Comparisons of time points vs. control (0 min) within either GT1-7 or SCN2.2 cells are indicated by:
a=p,0.05; b=p,0.01; c=p,0.001; d=p,0.0001. For Neuritin, where two-way ANOVA did not show a significant interaction between cell type and
treatment time, comparison between cell types as a whole (not broken down by treatment time) is indicated by ****=p,0.001, and comparison
between time points as a whole (not broken down by cell type) is indicated by a=p,0.05. Protein data were analyzed by paired samples t test for
control vs. 48 h; **=p,0.01; ***=p,0.001.
doi:10.1371/journal.pone.0023493.g005
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d=p,0.0001), 24 h (Figure 5C, d=p,0.0001), 36 h (Figure 5C,
d=p,0.0001) and 48 h compared to the control (Figure 5C,
c=p,0.001). Thus at all times tested Bid mRNA was higher in
GT1-7 treated cells vs. control. At several time points Bid mRNA
was higher in GT1-7 cells compared to SCN2.2, including 12 h
(Figure 5C, *=p,0.05), 24 h (Figure 5C, ****=p,0.0001), 36 h
(Figure 5C, ****=p,0.0001) and 48 h (Figure 5C, **=p,0.01).
GT1-7 cleaved Bid protein was measured after 48 h incubation
with Glu and compared with control by t-test; levels of cleaved Bid
protein were significantly higher after 48 h Glu treatment vs.
control (Figure 5C, ***=p,0.001). Unfortunately, we were
unable to obtain a satisfactory antibody against cleaved bid in
rats to test cleaved Bid protein levels in SCN2.2 cells.
Discussion
The SCN is the master biological clock of the body [5,6,28]. As
such, the SCN must communicate with the external environment
to assure that internal processes remain aligned with the
environmental light:dark cycle. Activation of the retinohypotha-
lamic tract by light releases Glu onto the SCN [29], leading to
activation of NMDARs on the postsynaptic SCN neurons [30,31]
to produce a calcium influx into the cells. Within the SCN
neurons, nocturnal light activates ERK/MAPK [32,33]; further-
more, blocking ERK/MAPK activation prevents the light
response within the SCN neurons [27]. Thus, both glutamate
and ERK/MAPK are important signal transducers required for
gating mechanisms involved in clock function.
Induction of ERK/MAPK is commonly associated with cell
survival [34,35,36] through activation of 2 different signaling
molecules: 1) cAMP response element binding protein (CREB)
(cAMP=cyclic adenosine monophosphate) [33]; and 2) mamma-
lian target of rapamycin (mTOR) [33,37]. CREB activation is
important in transcription of genes, many of which promote cell
survival; mTOR similarly supports survival via translational
control [38]. Correspondingly, in the SCN, inhibition of CREB
or mTOR blocks the physiological effects of nocturnal light [37].
Previously, we demonstrated that the SCN neurons are resistant to
Glu excitotoxicity [1]. Because ERK/MAPK is fundamental to
transducing the glutamatergic signal in the SCN, we hypothesized
that ERK/MAPK activation may also serve to allow SCN2.2 cells
to survive the Glu barrage that would be devastating to many
other neuronal types.
Our results indicate that resistance to Glu excitotoxicity in
SCN2.2 cells is indeed dependent on ERK/MAPK signaling.
SCN2.2 cell viability is unaffected by 10 mM Glu (Figure 1).
However, pre-treatment of SCN2.2 cells with an ERK/MAPK
inhibitor (PD98059) renders these cells susceptible to the
excitotoxic effects of Glu (Figure 1), and leads to activation of
caspase-dependent apoptosis (Figures 2 and 3). To the best of our
knowledge, this is the first report of a signal transducer that plays a
role conferring resistance against Glu insult in SCN2.2 cells.
Although extensively studied for promoting cell survival and
inhibiting apoptosis in cancer cells [39], more recent studies
demonstrate the neuroprotective effects of ERK/MAPK activity
in neuronal systems. ERK/MAPK activation reduces neuronal
damage incurred by ischemia-hypoxia. BDNF treatment results in
ERK/MAPK activation up to 12 h following ischemic-hypoxic
injury in neonatal brain and reduces the lesioned area as
compared to vehicle treatment alone; this is prevented by
inhibition of ERK/MAPK [40]. BDNF treatment prevents
camptothecin-induced cortical neuronal death, in an ERK/
MAPK-dependent manner [41]. Furthermore, resveratrol and
fisetin prevent neuronal death in a Huntington’s disease model via
ERK/MAPK activation [42]. Reperfusion injury following spinal-
cord ischemia can be reduced by a post-conditioning mechanism
that requires ERK/MAPK [43]. In axotomized retinal ganglion
neurons neurodegeneration can be prevented by VEGF (vascular
endothelial growth factor) via ERK/MAPK activation [44].
Finally, estrogen-dependent activation of ERK/MAPK inhibits
cell death in hippocampal neurons after global cerebral ischemia
[45].
Most of the studies highlighted above reported a single time-
point of ERK/MAPK activation. In the current study, we have
established a time-course for ERK/MAPK activation in SCN2.2
and GT1-7 cells. ERK/MAPK activation in response to Glu is
initially inhibited in the GT1-7 neurons and though it is increased
at 4 h, it falls to control levels at the end of 12 h (Fig. 3A) and
remains low at 48 h (Fig. 4A). However, SCN2.2 cells display a
sustained increase in ERK/MAPK up to 48 h (Fig. 3A and 4A),
which might be interpreted as a continuous presence of
neuroprotective factor (ERK/MAPK) in SCN2.2 cells in response
to Glu. It should be noted here that ERK/MAPK activation can
also be deleterious to neurons. Some studies show that inhibition
of ERK/MAPK activation prevents neuronal death (reviewed in
Zhuang S; Perspectives in Pharmacology; 2006). In our hands,
basal pERK levels were also much lower in the SCN2.2 untreated
cells as compared to the GT1-7 basal levels. The reasons for this
remain unclear.
Because the two other MAPK pathways have also been coupled
to cell death or proliferation, we examined Glu-induced activation
of the p38/MAPK and SAPK/JNK. Although consensus dictates
that p38/MAPK mediates cell death [24,46,47], contradictory
studies suggest a cell survival role for p38 [48]. We found that
phosphorylated (activated) p38 levels did not change with Glu
treatment in the SCN2.2 cells in the short time-course (Fig. 3B) or
at 48 h (Fig. 4B). However, a significant increase in p-p38 levels in
the GT1-7 cells during the short time-course (Fig. 3B) and at 48 h
(Fig. 4B) was observed. These data are highly suggestive of
preferential activation of a pro-survival ERK/MAPK pathway in
SCN2.2 cells as opposed to pro-apoptotic p38/MAPK activation
in the GT1-7 cells.
Diverse studies paradoxically implicate the SAPK/JNK path-
way in both apoptosis [26,49] and cell survival [50]. Neurode-
generation in Alzheimer’s disease has been related to long-term
activation of SAPK/JNK [51]. Overactivation of JNK is
associated with glial enlargement [52] and mediation of beta-
amyloid toxicity (Hashimoto, 2003). These responses seem to be
triggered by long-term activation of SAPK/JNK [53,54].
However, other studies indicate that a relatively short-term
activation of SAPK/JNK is essential for neurite outgrowth
[55,56] [57], neuronal development, and neuronal regeneration
[57].
In the current study, phosphorylated (activated) SAPK/JNK
levels did not change with Glu treatment in the GT1-7 cells
(Fig. 3C and 4C); however, pSAPK/JNK was transiently increased
in the SCN2.2 cells peaking at 30 min and then returning to
baseline levels (Fig. 3C) and remaining low up to 48 h (Fig. 4C).
We speculate that it is the ability of the SCN2.2 cells to respond to
stress through transient pSAPK/JNK activation which may, in
turn, activate more long-term mechanisms that prevent these cells
from undergoing apoptosis in the face of glutamatergic challenge.
Signaling downstream of the ERK/MAPK, particularly related
to CREB and mTOR activity is important in cell survival. This
study examined the effects of Glu on transcript levels of two CREB
target genes, Bcl2 and neuritin [58]. Neuritin is required for
neurite outgrowth [59,60,61]. Bcl2 is well-studied as an anti-
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[66,67,68,69]. Thus, it is possible that strong upregulation of
Bcl2 may confer protection on the SCN2.2 cells. However, in our
study, we did not find any change in the neuritin mRNA levels
with Glu treatment in either the GT1-7 or SCN2.2 cells (except at
36 h, Fig. 5A). Neuritin protein levels also remained unchanged in
the SCN2.2 and GT1-7 cells with Glu treatment (Fig. 5A). As
opposed to our expectation, Bcl2 mRNA was initially increased in
the GT1-7 cells, but showed no change with time in the SCN2.2
cells (Fig. 5B). We speculate that the temporary increase in Bcl2
mRNA in GT1-7 cells may represent an initial protective
response, which is overwhelmed by continued Glu toxicity.
Surprisingly, while the Bcl2 mRNA levels remained unchanged
with Glu treatment in the SCN2.2 cells, Bcl2 protein was
significantly increased in the SCN2.2 cells at 48 h. This suggests
an additional mechanism activated downstream of ERK/MAPK
signaling, which provides neuroprotection to the SCN2.2 cells
against Glu.
Bid is a pro-apoptotic molecule whose cleavage triggers
formation of the Bax channel [70], thus allowing cytochrome-c
to be released from the mitochondria into the cytosol [71]. This in
turn results in formation of the apoptosome, leading to caspase 3
activation and ultimately, cell demise. We found that Glu
treatment resulted in a strong increase in the Bid mRNA levels
in the GT1-7, but not in the SCN2.2 cells (Figure 5C). Bid mRNA
levels were significantly increased over a period of 12 to 48 h in
the Glu-treated GT1-7 cells but remained steady in the SCN2.2
cells and did not change with respect to untreated control
(Figure 5C). The cleaved fragment (activated) Bid appeared in the
Glu-treated GT1-7 cells at 48 h, but not in the untreated control
(Figure 5C). We were unable to find an appropriate antibody for
determining cleaved Bid in SCN2.2 cells. However, these results
clearly demonstrate the activation of different pathways in
response to Glu in the 2 cell types: a pro-survival ERK/MAPK
in the SCN2.2 neurons as opposed to a pro-apoptotic pathway in
the GT1-7 neurons.
Porterfield et al., 2007 [72], identified a total of 13 transcripts
that were significantly increased in the SCN 30 min after
administration of a light pulse. Among these, of interest are genes
such as Pim3 (a Ser/Thr kinase), Btg2 and Klf4, all of which have
established anti-apoptotic functions in non-neuronal systems.
Their role in neurons, more specifically in the SCN neurons, is
currently unknown. Future studies should attempt to explore the
significance of these genes in SCN neurons.
Functional NMDARs on the post-synaptic SCN neurons
[73,74] are required for the physiological response to nocturnal
light in the SCN [75,76]. NMDAR inhibition in the SCN blocks
the effects of light in vivo and its correlate, Glu, in vitro [75,76].
However, innumerable studies have implicated the NMDARs in
mediating Glu excitotoxicity in various neuronal populations
[77,78]. In the present study, NMDA and Glu induced cell death
in the GT1-7 neurons, while leaving the SCN2.2 neurons
unaffected. Glu and NMDA toxicity in GT1-7 cells was blocked
by the NMDAR antagonist MK-801. Furthermore, SCN2.2 cell
death induced in the presence of NMDA and the ERK/MAPK
inhibitor was blocked by MK-801. These data suggest that
NMDAR signaling lies upstream of the ERK/MAPK signaling
response to Glu in the SCN2.2 cells.
The complex nature of cell signaling pathways suggests the
possibility that numerous signaling events may be involved in
conferring resistance to excitotoxicity in SCN2.2 cells. SCN
neurons project onto largely GABAergic, neurons within and
outside the nucleus [79]. This raises the possibility that the SCN
neurons in vivo are able to tolerate large glutamate release simply
because this excitatory transmission serves largely to increase
inhibition. However, in the current study, we have used SCN2.2
cells which lack the enzyme needed to synthesize GABA [80].
Thus, it is unlikely that release of GABA explains all of the
endogenous resistance to excitotoxicity in the SCN2.2 cells. Future
studies will be performed in vivo to explore the role of GABA
neurotransmission in determining resistance of SCN neurons to
excitotoxic damage.
Another alternative is that SCN2.2 cells simply lack NMDARs
and are incapable of responding to an excitotoxic insult.
Experiments performed by Menger et al in 2005, indentified
transcripts associated with glutamatergic signaling [80]. Previous
work from our lab has established the presence of transcripts
(NR1, NR2A and NR2B) and protein products (NR1 and NR2A/
NR2B) of NMDAR subunits in the SCN2.2 cells [1]. In the same
study, we used a luciferase reporter assay to demonstrate the
functional activity of the NMDARs in SCN2.2 cells. The luciferase
reporter was linked to DNA regions known to be activated in
response to glutamate in the SCN. Glutamate treatment increased
the luciferase activity in the SCN2.2 cells; this was attenuated by
the NMDAR antagonists MK-801 and AP-5. Collectively, these
results serve to establish that the SCN2.2 cells are capable of
responding robustly to glutamate.
It is common knowledge that the SCN in vivo is enriched in
astrocytes. This raises the possibility that rapid glutamate uptake
by glia prevents SCN neurons from exposure to excitotoxic
damage. However, it should be noted that in the current study, we
have used the SCN2.2 cell line, which is typically comprised of
about 95% neurons and 5% glia. While culturing SCN2.2 cells, we
use cell culture flasks which have surfaces coated with Poly D-
Lysine. This prevents rapid glial proliferation in vitro. Also, a
recent study from our lab [1] demonstrated that Inhibition of
glutamate transporters did not increase the susceptibility of
SCN2.2 cells to glutamate excitotoxicity. It is therefore unlikely
that glial uptake of glutamate is the sole mechanism for protection
of SCN2.2 cells from excitotoxicity.
SCN and their immortalized counterparts, SCN2.2 cells, are
commonly investigated for their rhythmic nature. Whether
rhythmicity contributes to protection from excitotoxicity remains
an open question. It is possible ERK, p38 and SAPK/JNK have
different peaks of activation and that the timing of their activation
is key to determining the resistance to excitotoxic damage. The
present study did not attempt to address this question. In our
hands, cultures of SCN2.2 cells are arrhythmic unless a stimulus
such as serum shock is first used to synchronize the culture. All
experiments for this manuscript were performed on unsynchro-
nized cultures. It would indeed be interesting to determine
whether the timing of activation of the MAPK proteins render the
SCN2.2 cells more or less susceptible to excitotoxic damage, and
these experiments could easily be performed in the future in
synchronized SCN2.2 cells.
Several lines of evidence support the similarity and disparity of
the SCN2.2 cells with the SCN in vivo. SCN lesions result in loss
of circadian rhythms, which can be restored by implantation of
SCN2.2, cells in vivo [81]. A study performed by Menger GJ, et al
in 2005 [80] performed exhaustive profiling of genes in the
SCN2.2 cells and compared them to the SCN in vivo. They found
a significant overlap between the expression patterns of numerous
genes between these two cell types. When they synchronized the
SCN2.2 cells, they found that many of the same genes that were
rhythmic in rat SCN were also rhythmic in the SCN2.2 cells. It
would be interesting to determine which of these genes are also
responsive to light-induced transcription and have a role in
neuroprotection.
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construction of a hypothetical model for neuroprotection in the
SCN (Figure 6). Activation of NMDARs on SCN neurons results
in robust and prolonged activation of ERK/MAPK, which, in
turn, promotes activation of downstream anti-apoptotic factors
(such as Bcl2) and prevents SCN2.2 cell death. Blocking ERK/
MAPK enables Glu to induce excitotoxicity by activating caspase
3-dependent apoptosis. Further experimentation into these
mechanisms will help to determine the differences between
signaling pathways activated in cells resistant to Glu toxicity as
opposed to cells that are susceptible to Glu insult. Thus, future
studies will build upon the current findings in moving toward the




Glu (an excitotoxin), PD98059 (ERK/MAPK inhibitor), MK-
801 (use-dependent NMDAR antagonist) and NMDA (an
excitotoxin) were purchased from Sigma.
Cell culture
The SCN2.2 cells (a gift from Dr. D. Earnest, Texas A&M
University) were cultured in Minimum Essential Medium (MEM),
supplemented with 7.5% Bovine growth serum (BGS), 10,000
Units/ml penicillin, 10,000 Units/ml streptomycin, 250 mg/ml
fungizone on poly-D-lysine-coated T75 flasks. The GT1-7 cells (a
gift from Dr. P. Mellon, University of California, San Diego) were
cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 7.5% BGS, 4.5 gm/L glucose, 2 mM L-
glutamine and 10,000 Units/ml penicillin, 10,000 Units/ml
streptomycin, 250 mg/ml fungizone, on uncoated plates. Cells
were incubated at 37uC with 5% CO2. All cultures were grown to
50% confluence before treatment.
Live vs. dead Total cell analysis
Cells were plated in 96-well plates at 5000 cells per well.
Treatments were initiated when cultures reached 50% confluence.
Inhibitors were added 1 h prior to onset of treatment and
maintained throughout the treatment period. Fresh medium was
placed in the control (untreated) wells. The Live/Dead assay kit
(Invitrogen) was used to analyze cell viability. In this assay, the cell
membrane permeable dye Calcein AM is metabolized to the
fluorescent green dye Calcein which is cell non-permeable. Dead
cells are measured by the DNA binding dye Ethidium homodimer-
1, which fluoresces red upon binding to DNA. This dye cannot
enter the cell unless the membrane is already damaged, and so
does not tag healthy cells. Optical density was measured for each
sample using the Fluoroskan 96 well plate reader (MTX Lab
Systems). For the green Calcein staining living cells, excitation is
485 nm and emission is 538 nm. For the red Ethidium
homodimer-1 staining dead cells, excitation is 544 nm and
emission is 590 nm.
MTS Assay
Cells were plated in 96 well plates at 5000 cells per well and
treated at 50% confluence. Inhibitors were added 1 h before
treatment was initiated and maintained throughout the treatment
period. Fresh medium was placed in the control (untreated) wells.
For the assay, 100 ml of medium was removed from each well.
20 ml of MTS reagent (CellTiter 96 Aqueous One Solution Cell
Proliferation Assay, Promega) was added to each well. The cells
were incubated at 37uC in 5% CO2 for 1–4 h, in accordance with
manufacturer’s protocol. After color development, the plate was
read at 490 nm (800EL Universal Microplate Reader, Bio-Tek
Figure 6. Hypothetical Model for Neuroprotection in SCN2.2 Cells. Glu activates NMDAR, causing an increase in calcium into the cell. Under
normal conditions, this leads to a phosphorylation and activation of ERK/MAPK and ultimately cell survival. Bcl2 protein levels are increased, partially
explaining the failure to activate caspase 3 and undergo apoptosis in response to excitotoxin. When ERK/MAPK is inhibited with PD98059, this
survival pathway is blocked. Caspase 3 activity rises, and the cells undergo apoptosis. The cell signaling pathway connecting NMDAR activity and cell
death under conditions of ERK/MAPK inhibition is unknown at present, but it is possible that activation of p38/MAPK as well as reduction in Bcl2 lead
to caspase activity and cell death.
doi:10.1371/journal.pone.0023493.g006
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metabolic activity with respect to untreated control.
TUNEL assay
Cells were grown in T25 flasks and treated at 50% confluence.
Inhibitors were added 1 h before treatment was initiated and
maintained throughout the treatment period. Fresh medium was
placed in the control (untreated) flasks. The TUNEL assay was
performed with the FragEL DNA Fragmentation Detection Kit
(Calbiochem), at the end of 48 h of Glu treatment, according to
the manufacturer’s specifications. Coverslips were mounted with
DAPI in antifade solution. Negative controls included omission of
the TdT enzyme. Alternatively, TUNEL was performed with the
Apoptag Apoptosis Detection System (Chemicon, Temecula, CA)
according to the manufacturer’s specifications. Slides were
mounted with DAPI in antifade solution. Negative controls
included omission of the TdT enzyme or the anti-Digoxigenin
antibody. Images were taken using the Zeiss Axiovert 200
microscope equipped with a digital camera. The entire set of
treatments followed by the TUNEL assay was performed in
triplicate. Cells positive for fluorescein stained the apoptotic
TUNEL-positive cells. Total cells were counted by two indepen-
dent observers, each blind to experimental condition. Apoptotic
cells were quantified using the formula:
% TUNEL positive~ TUNEL positive cells=total cells ðÞ |100:
Protein extraction for Western blotting
Medium was removed and cells were washed with PBS. Tissue
Protein Extraction Reagent (T-PER; Pierce, Rockford, IL),
containing 16 Protease Inhibitor (Roche, Indianapolis, IN), was
added. Phosphatase inhibitors (Phosphatase inhibitor cocktail 1,
Sigma and Phosphatase inhibitor cocktail 2, Sigma) were also
added to the extraction reagent (1 ml of each for every 100 mlo f
the extraction reagent). Cells were scraped into the extraction
solution and placed into microfuge tubes. Tubes were spun at
10,000 rpm for 5 min (at 4uC) to precipitate cellular debris.
Supernatants were placed in fresh microfuge tubes and stored at
280uC. Protein concentration in supernatants was determined by
using the Pierce BCA Protein Assay Kit (Thermo Scientific) as per
the manufacturer’s protocol.
Western Blotting
Cells were grown in T25 flasks and treated at 50% confluence.
Inhibitors were added 1 h prior to treatment and were present
throughout the treatment period. Fresh medium was placed in the
control (untreated) flasks. At the end of the treatment period, the
medium was removed and the protein was extracted and assayed
as described above. 80–100 mg of protein was resolved by SDS-
PAGE and transferred to a nitrocellulose membrane. The
membrane was blocked with 5% non-fat dry milk (LabScientific,
Inc.) dissolved in 0.05% Tris buffered saline – Triton (TBS-T;
50 mM Tris-HCl, 150 mM NaCl, pH 7.5+50 ml/100 ml Triton-
X 100) at room temperature for 1 h. Membranes were washed
with 0.05% TBS-T and incubated overnight at 4uC in primary
antibody: phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
rabbit monoclonal antibody (1:2000) (Cell Signaling); phospho-
p38 MAPK mouse antibody (1:2000) (Cell Signaling); p44/42
MAPK (Erk1/2) mouse monoclonal antibody (1:2000) (Cell
Signaling); Beta-Actin mouse antibody (1:5000) (Sigma) or tubulin
mouse antibody (1:5000) (Sigma). The latter two were used as
loading controls. The primary antibody solution was removed and
the membrane was washed 3 times with 0.05% TBS-T, for 10 min
each. The membrane was then treated with anti-rabbit antibody
(Odyssey LiCor, IR800) (1:5000) or anti-mouse antibody (Odyssey
LiCor, IR700) (1:5000) for 1 h at room temperature. The
secondary antibody solution was removed and the membranes
were washed 3 times with 0.05% TBS-T, for 10 min each. All the
antibody dilutions were made in SuperBlock Blocking Buffer in
TBS (Thermo Scientific). The blots were analyzed using the LiCor
Odyssey infrared imaging and densitometric analysis was per-
formed using the LiCor Odyssey software.
Caspase 3 activity assay
Cells were grown in T75 flasks. Treatments were initiated at
50% confluence. At the end of 48 h, the medium was removed
and the cells were washed with phosphate buffered saline (PBS).
Caspase 3 activity assay was performed using the caspase 3
Colorimetric Assay kit (R&D Systems), as per the manufacturer’s
protocol. A small portion of the lysate from the samples was saved
for protein assay. Protein quantification was done using the Micro
BCA Protein Assay Kit (Thermo Scientific), as per the manufac-
turer’s protocol. Caspase 3 activity per mg of protein was
measured and relative increase or decrease was measured using
the untreated control as a standard. A standard curve was
prepared. All experiments were performed in triplicate.
Immunocytochemistry
Cells were cultured on coverslips in a 24-well plate. The
treatments were done at 50% confluence. Inhibitors were added
1 h prior to onset of treatment. At the end of the 48 h treatment
period, the medium was removed. Cells were washed with 1 ml of
Dulbecco’s Phosphate Buffered Saline (DPBS) per well. The DPBS
was removed and 200 ml of 2% paraformaldehyde (PFA) in DPBS
was added to each well. The cells were fixed for 15 min in PFA.
The cells were rinsed 3 times, 5 min each, with PBS and blocked
for 1 h with 5% goat serum in 0.3% PBS-Triton-X 100 (PBS-T).
Cells were then incubated overnight at 4uC, in primary antibody.
The cells were washed 3 times, 10 min each, in PBS-T. The
secondary antibody treatment was done for 1 h at room
temperature in the dark. Cells were again washed with PBS-T, 3
times, 5 min each. The coverslips were then mounted onto slides
using Vectashield.
Treatments for mRNA quantification
Cells were cultured in 6 well plates. At 50% confluence, 10 mM
Glu was added to half the wells. Medium without Glu was placed
in the untreated control wells. At each time-point (1, 6, 12, 18, 24,
36, 48, 60 and 72 h) the medium was removed. Cells were washed
with 0.01 M PBS. 1 ml TRIzol (Invitrogen) solution was added
per well. The plate was kept at 280uC until analysis.
RNA extraction
Samples were incubated in TRIzol at room temperature for
15 min to allow dissociation of nucleoprotein complexes. RNA
was extracted into the aqueous phase by addition of 0.2 ml
chloroform per 1 ml TRIzol. The chloroform/TRIzol mixture
was vortexed for 15 s, kept at room temperature for 2–3 min and
centrifuged at 12,000 rpm for 15 min. The colorless aqueous
phase that contains RNA was transferred to a fresh RNase-free
tube. Isopropyl alcohol (0.5 ml/1 ml TRIzol originally used) was
added. The co-precipitate Glycoblue (1 ml) was added to each tube
to aid in visualization of the RNA pellet. Linear acrylamide (1 ml)
was added to increase RNA yield. This mixture was kept at
Neuroprotection in the SCN
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12,000 rpm. The RNA pellet was washed with 1 ml of 75%
ethanol (in DEPC-water) and air dried. The RNA pellet was then
dissolved in DEPC-water (Fisher Bioreagents). Concentration of
the RNA was determined using the NanoDrop ND-1000 UV
spectrophotometer at 260 nm and 280 nm. Purity of the samples
was determined by checking the 260/280 and the 260/230 ratios.
Negative controls included omission of RNA template and
omission of the reverse transcriptase (RT) enzyme.
Quantitative PCR
The Bid primers from mouse were designed using NCBI Primer
Blast; forward primer: GCCGAGTGTGGCTCCGCAAA and
reverse primer: CCGGAACCGTTGCTGACCT. All other
primers were purchased from Qiagen and the sequences are
proprietary. qPCR reactions were performed in duplicate in the
Smart Cycler (Cepheid). Standard curves were performed for each
of the primers as previously described [1]. Results of the standard
curves are given in Table 2.
Statistics
Two-way ANOVA with Bonferroni’s post hoc test for multiple
comparisons was used to analyze effects of cell type and treatment.
Effects of cell treatment on a single cell type were analyzed with
repeated measures ANOVA and Tukey’s post hoc test. Means of
control and 48 h treatment were compared with paired t test. All
statistics were performed with GraphPad Prism 5.0 software.
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